Dual Antiplatelet Therapy for Shock Patients with Acute Myocardial Infarction - DAPT SH












            ******************************************************************************************

            *
            ******************************************************************************************
            Number: MA/25/F1/0/010

            Flagship: 1 - Urban Health and Demographic Change
            Faculty: 3LF
            Project leader: Moťovská, Zuzana

            Cardiogenic shock (CS) is a devastating and often fatal complication of acute myocardial i
            with a high risk of death despite urgent intervention. CS can influence how medications ar
            act in the body. The DAPT-SHOCK-AMI trial is the first randomized, multicentre, placebo-co

            evaluate whether cangrelor, an intravenous P2Y12 inhibitor, can improve outcomes for patie
            undergoing primary angioplasty. Conducted in five countries and involving 605 patients, th

            intravenous cangrelor with ticagrelor administered as crushed tablets at a loading dose of
            primary endpoint is a composite of all-cause death, myocardial infarction or stroke within
            The project will follow patients for five years to determine the long-term effects of the 

            antithrombotic strategy on the risk of heart failure and to guide secondary prevention aft
            infarction in the highest-risk patients. The research team is also working on the PRE-DAPT
            led by Zuzana Moťovská at Charles University, which aims to initiate cangrelor treatment a

            of contact through emergency medical services to address the high mortality before hospita
            The international consortium includes the Icahn School of Medicine at Mount Sinai, the Uni
            of Freiburg, the University of Tübingen, Jagiellonian University and Nicolaus Copernicus U

            Collaboration within this network has also led to joint participation in major European in
            as the Horizon 2020-supported RITA 2 study organised by Université Paris-Cité and INSERM.